Regulatory
FDA Clears the First-Ever Generic of a Radioactive Cancer Drug
Curium’s Bexlutry, a generic of Novartis’s Lutathera, is the first “radioligand equivalent” approved in the U.S. — a milestone that could open a fast-growing but supply-constrained corner of cancer care to competition.